The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical deve...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Study protocol Source Type: research

Related Links:

Publication date: 14–20 September 2019Source: The Lancet, Volume 394, Issue 10202Author(s): Christoph Lange, Keertan Dheda, Dumitru Chesov, Anna Maria Mandalakas, Zarir Udwadia, C Robert HorsburghSummaryDrug-resistant tuberculosis is a major public health concern in many countries. Over the past decade, the number of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase. Globally, 4·6% of patients with tuberculosis have multidrug-resistant tuberculos...
Source: The Lancet - Category: General Medicine Source Type: research
Conclusions: Adherence to ART was higher than to MDR-TB treatment among persons with MDR-TB/HIV coinfection. Missed clinic visits may be a simple measure for identifying patients at risk of unsuccessful MDR-TB treatment outcome.
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - Category: Infectious Diseases Tags: Epidemiology Source Type: research
Microbial Drug Resistance, Ahead of Print.
Source: Microbial Drug Resistance - Category: Microbiology Authors: Source Type: research
Tuberculosis (TB), which is estimated to be the deadliest infectious disease worldwide with ~1.6 million deaths yearly [1], is a clinical issue due to the "ancient" diagnostics and drugs currently available. If compared with the management of other highly prevalent infectious diseases, such as HIV/AIDS and hepatitis C virus infection, it is clear that the clinical approach for TB disease requires innovation, being still based on means with limited efficacy (e.g. treatment of multidrug-resistant TB; MDR-TB), and characterised by the denominator "long duration": conventional bacteriological diagnosis, the...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
To investigate the prevalence and factors associated with the prevalence of multidrug/rifampicin-resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research article Source Type: research
Several key new developments regarding drug-resistant tuberculosis are outlined in this Commission Update, including detail on the WHO guidelines on treating drug-resistant tuberculosis which were updated in2019 with a reclassification of second line anti-tuberculosis drugs.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Prevalence of diabetes mellitus (DM) in patients with tuberculosis (TB) is increasing and may negatively impact TB outcomes in patients with active disease [1]. Gastrointestinal problems, including gastroparesis, may result in delayed drug absorption or malabsorption in patients with DM, which may cause suboptimal drug exposure and poor outcome [2]. Studies on the pharmacokinetics of the first-line anti-TB drugs in patients with DM yielded conflicting results on low drug exposure [3–7]. Moxifloxacin is a potent bactericidal drug against Mycobacterium tuberculosis and is key for the treatment of multidrug-resistant tu...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
Publication date: September 2019Source: The Lancet Respiratory Medicine, Volume 7, Issue 9Author(s): Keertan Dheda, Tawanda Gumbo, Gary Maartens, Kelly E Dooley, Megan Murray, Jennifer Furin, Edward A Nardell, Robin M Warren, Keertan Dheda, Tawanda Gumbo, Gary Maartens, Kelly E Dooley, Aliasgar Esmail, Megan Murray, Jennifer Furin, Edward Nardell, Leslie London, Erica Lessem, Jason Limberis, Grant TheronSummaryThe Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was published in 2017, which comprehensively reviewed and provided recommendations on various aspects of the disease. Several key new developm...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Environmental bacteria, nontuberculous mycobacteria (NTM), are recognized as one of the major human infection pathogens. NTM are prone to be mistaken as multidrug-resistant Mycobacterium tuberculosis and challeng...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research article Source Type: research
Abstract A patient who had initial infection with mixed strains of drug-susceptible and multidrug-resistant tuberculosis was presumed to have acquired drug resistance before confirmation that sequential strains were genotypically distinct. Transmitted infection with mixed strains is likely underappreciated; identifying these infections requires spoligotyping and whole-genome sequencing. PMID: 31454310 [PubMed - as supplied by publisher]
Source: Emerging Infectious Diseases - Category: Infectious Diseases Authors: Tags: Emerg Infect Dis Source Type: research
More News: Bedaquiline | Infectious Diseases | Marketing | Multidrug Resistance | Study | Tuberculosis